Preclinical Antibody Development Global Market Report 2026

The preclinical antibody development market size has grown rapidly in recent years. It will grow from $4.77 billion in 2025 to $5.27 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to rising demand for therapeutic antibodies, advances in monoclonal antibody technologies, growth of oncology and infectious disease research, improvements in laboratory automation, increasing r&d investments by pharmaceutical companies.

The preclinical antibody development market size is expected to see rapid growth in the next few years. It will grow to $7.93 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to adoption of ai-based antibody design platforms, integration of predictive analytics in preclinical studies, expansion of biotechnology research infrastructure, growing focus on personalized medicine, increasing collaborations between pharmaceutical and biotech companies. Major trends in the forecast period include high-throughput antibody screening, ai-driven candidate optimization, advanced in vitro assays, predictive toxicity modeling, early-stage developability assessment.

The rising prevalence of autoimmune diseases is anticipated to drive the growth of the preclinical antibody development market over the forecast period. Autoimmune diseases are a group of disorders in which the immune system erroneously attacks healthy cells and tissues, causing chronic inflammation and tissue damage. The increase in these conditions is fueled by a combination of genetic predisposition, environmental and lifestyle factors, alterations in immune-modulating exposures, and enhanced disease awareness and diagnostic capabilities. The growing impact of autoimmune diseases has created substantial unmet medical needs, motivating pharmaceutical and biotechnology companies to intensify research and development efforts aimed at targeted biologic therapies. Preclinical antibody development is crucial in this process, as it enables the discovery, screening, and optimization of antibodies intended to selectively modulate or suppress dysregulated immune responses before clinical evaluation. For example, in February 2024, Arthritis Australia, an Australia-based non-profit organization, reported that the number of males with rheumatoid arthritis (RA) (an autoimmune disease) is 212,136 and females 362,137 in 2025, with projections for 2040 estimating approximately 280,040 males and 479,828 females. Hence, the increasing prevalence of autoimmune diseases is propelling the growth of the preclinical antibody development market.

Key companies operating in the preclinical antibody development market are increasingly focusing on the development of innovative modalities such as antibody-drug conjugates (ADCs) to enhance targeted cancer therapies and improve treatment efficacy. ADCs are a class of targeted therapeutics that combine the specificity of monoclonal antibodies with the potent cytotoxic activity of small-molecule drugs, enabling selective delivery of toxic payloads to cancer cells while minimizing damage to healthy tissues. For example, in November 2024, Celltrion Inc., a South Korea-based biopharmaceutical company, announced the development of CT-P70 and CT-P71, two novel preclinical ADC candidates targeting solid tumors, including non-small cell lung cancer and bladder cancer, respectively. Both ADCs consist of tumor-targeting antibodies conjugated to cytotoxic payloads, designed to achieve precise tumor targeting with reduced off-target toxicity, potentially improving therapeutic indices compared to conventional monoclonal antibodies or chemotherapies. Such next-generation ADC programs reflect a broader industry shift from biosimilar manufacturing toward the development of novel, differentiated biologic therapies.

In May 2024, Genmab A/S, a Denmark-based biopharmaceutical company, acquired ProfoundBio for an undisclosed amount. Through this acquisition, Genmab intends to enhance its preclinical antibody development capabilities and accelerate its pipeline of innovative therapeutics. ProfoundBio Inc. is a China-based biotechnology company that focuses on preclinical antibody discovery and development services for next-generation biologics.

Major companies operating in the preclinical antibody development market are Thermo Fisher Scientific Inc., WuXi AppTec Co Ltd., Charles River Laboratories International Inc., Sartorius Aktiengesellschaft, Samsung Biologics Co. Ltd., Evotec SE, KBI Biopharma Inc., GenScript Biotech Corporation, Abzena plc, Crown Bioscience Inc., AbCellera Biologics Inc., Adimab LLC, Creative Biolabs Inc., Boehringer Ingelheim BioXcellence GmbH, Integral Molecular Inc., ProMab Biotechnologies Inc., Eurofins Scientific SE, Ablexis Inc., Mabsilico Inc., Fujifilm Diosynth Biotechnologies Inc., Recipharm AB.

North America was the largest region in the preclinical antibody development market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical antibody development market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the preclinical antibody development market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The preclinical antibody development market includes revenues earned by entities through monoclonal antibody discovery services, antibody engineering and optimization, preclinical testing and validation, contract research services, and licensing and royalties. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Preclinical antibody development is the stage of therapeutic antibody research that follows initial discovery and precedes clinical trials in humans. It focuses on optimizing antibody candidates and evaluating their safety, efficacy, and manufacturability. This phase involves engineering and characterizing antibodies through in vitro assays and in vivo animal studies to examine target binding, mechanism of action, pharmacokinetics, potential toxicity, and includes early-stage manufacturing and formulation efforts.

The primary types of preclinical antibody development include monoclonal antibodies, polyclonal antibodies, and other variants. Monoclonal antibodies are highly specific antibodies produced from a single clone to target a unique antigen for research or therapeutic purposes. Services include antibody discovery, humanization and engineering, affinity maturation, developability assessment, expression and purification, and in vitro functional characterization. Applications cover oncology, infectious diseases, autoimmune diseases, and others, serving pharmaceutical companies, biotechnology firms, research institutes, and other end users.

Tariffs have influenced the preclinical antibody development market by raising the cost of importing laboratory instruments, reagents, and specialized antibodies, impacting segments such as monoclonal and polyclonal antibodies. Regions like North America and Europe, which depend heavily on imports for advanced research tools, are most affected. In response, companies are investing in local production and alternative sourcing strategies, which can enhance supply chain resilience and foster innovation in cost-efficient preclinical development solutions.

The preclinical antibody development market research report is one of a series of new reports that provides preclinical antibody development market statistics, including preclinical antibody development industry global market size, regional shares, competitors with a preclinical antibody development market share, detailed preclinical antibody development market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical antibody development industry. This preclinical antibody development market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.